What occurs in the other 20% of cancer patients with chemotherapy-induced nausea and vomiting (CINV)? A single-institution qualitative study.
What occurs in the other 20% of cancer patients with chemotherapy-induced nausea and vomiting (CINV)? A single-institution qualitative study.
复制标题
DOI：
10.1007/s00520-018-4323-x
复制
发表时间：
2019-01
期刊：
影响因子：
--
通讯作者：
Jatoi A
中科院分区：
文献类型：
--
作者：
Childs DS;Looker S;Le-Rademacher J;Ridgeway JL;Breitkopf CR;Jatoi A
尽管最近在预防和管理方面取得了进展，但20%接受中度至重度致吐化疗的患者仍会出现恶心和呕吐。依靠患者自己的话，这项研究试图捕捉和描述这个重要的患者亚组的化疗诱导的恶心和呕吐（CINV）的生活经历。有CINV控制不佳病史的实体瘤患者提供知情同意书，并参加半结构化访谈，该访谈是录音和转录的。在数据饱和后，停止招募;并采用归纳，定性分析方法。20例入组患者的中位年龄为56岁（范围：27，83），性别分布相同;一半患有胃肠道癌。出现了两个主题。首先，CINV是严重的和多方面的：“它就像撕碎你的肌肉......它一次又一次地这样做。”这种症状综合症具有心理社会含义：“孤立是一件大事。”财务毒性也牵连在内：“我使用[止吐药]时，我觉得它是绝对必要的，因为它是如此昂贵，我买不起它。”第二个主题是对症状的漏报。患者似乎接受N/V作为治疗的一部分，因此不太愿意透露：“上帝，如果你在你的系统中注入毒药，你必须期待一些副作用。这些生动的数据应该激励研究人员继续进行CINV的临床试验，并提醒医疗保健提供者关于患者教育的重要性，即突破性治疗的可用性。
Despite recent advances in prophylaxis and management, 20% of patients who receive moderately to severely emetogenic chemotherapy continue to experience nausea and vomiting. Relying on patients’ own words, this study sought to capture and characterize the lived experience with chemotherapy-induced nausea and vomiting (CINV) for this important subgroup of patients. Solid tumor patients with a history of poorly controlled CINV provided informed consent and participated in a semi-structured interview, which was audio-recorded and transcribed. After data saturation, enrollment ceased; and inductive, qualitative analytic methods were employed. The median age of the 20 enrolled patients was 56 years (range: 27, 83) with an equal gender split; half had gastrointestinal cancers. Two themes emerged. First, CINV is severe and multidimensional: “It’s like shredding your muscles… It’s doing it over and over again.” This symptom complex has psychosocial implications: “Isolation is a big thing.” Financial toxicity is also implicated: “I use [an antiemetic] when I feel like it is absolutely necessary because it is so expensive I cannot afford it anyway.” The second theme is underreporting of symptoms. Patients seemed to accept N/V as part of treatment and were therefore less forthcoming: “God, if you’re pumping poison in your system, you gotta expect some side effects.” These vivid data should motivate investigators to continue conducting clinical trials CINV and should remind healthcare providers about the importance of patient education on the availability of therapy for breakthrough symptomatology.
登录
查看更多内容
影响因子：
4.7
作者：
Passik, SD;Kirsh, KL;Theobald, DE
通讯作者：
Theobald, DE
DOI：
10.4997/jrcpe.2015.305
发表时间：
2015-01-01
影响因子：
1.4
作者：
Chapman, A. L.;Hadfield, M.;Chapman, C. J.
通讯作者：
Chapman, C. J.
影响因子：
50.5
作者：
Roila, F.;Molassiotis, A.;van der Wetering, M.
通讯作者：
van der Wetering, M.
影响因子：
--
作者：
Hesketh, Paul J.;Bohlke, Kari;Kris, Mark G.
通讯作者：
Kris, Mark G.
影响因子：
3.1
作者：
Kadakia, Kunal C.;Leal, Alexis D.;Seisler, Drew K.;Qin, Rui;Fee-Schroeder, Kelliann C.;Grendahl, Darryl C.;Sorgatz, Kristine M.;Loprinzi, Charles L.
通讯作者：
Loprinzi, Charles L.